Live Breaking News & Updates on Joshuaw Ruthizer

Stay updated with breaking news from Joshuaw ruthizer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock


Share this article
Share this article
NEW YORK, April 7, 2021 /PRNewswire/ Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock.
FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen s stock price to fall almost 25% to $38.07 per share. ....

New York , United States , Adam Feuerstein , Joshuaw Ruthizer , Wolf Popper , Joshua Ruthizer , Fibrogen Inc , Renal Drugs Advisory Committee , Prnewswire Wolf Popper , Advisory Committee , New Drug Application , Prior Results Do Not Guarantee , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஆடம் பேஉேர்சித்தேன் , ஓநாய் பாபர் , புதியது மருந்து விண்ணப்பம் , ப்ரையர் முடிவுகள் செய் இல்லை உத்தரவாதம் ,